



BAFNA PHARMACEUTICALS LTD.,

www.bafnapharma.com

REF : BPL/ 211/17-18

20.10.2017

To
The Bombay Stock Exchange Limited
PJ Towers, Dalal Street
Mumbai – 400 001

To
National Stock Exchange of India Ltd
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai 400 051

Dear Sir/Madam,

Sub: Statement of Investor Complaints - Regulation 13(3) of SEBI (LODR) Regulations, 2015
Ref: Quarter Ended September 30, 2017.

Please find enclosed the statement of Investor complaints of the company as per Regulation 13[3] of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the Quarter ended September 30, 2017.

Kindly acknowledge the receipt.

Thanking You,

For BAFNA PHARMACEUTICALS LIMITED

Managing Director



BAFNA PHARMACEUTICALS LTD.,

www.bafnapharma.com

REF : BPL/ 212/17-18

20.10.2017

To
The Bombay Stock Exchange Limited
PJ Towers, Dalal Street
Mumbai – 400 001

To
National Stock Exchange of India Ltd
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai 400 051

Dear Sir / Madam,

Sub: Statement of Investor Complaints - Regulation 13(3) of SEBI (LODR) Regulations, 2015
Ref: Quarter Ended September 30, 2017

With reference to the above we furnish hereunder the complaints report for the period from 01.07.2017 to 30.09.2017 for your reference and records:

No. of Complaints pending at the beginning of the quarter	- NIL
No. of Complaints received during the quarter	- NIL
No. of Complaints disposed of during the quarter	- NIL
No. of Complaints remaining unresolved as on 30.09.2017	- NIL

Thanking You

For BAFNA PHARMACEUTICALS LIMITED

Managing Director